SCHEMBL579788

SCHEMBL579788

CCCCC(CC)COc1ccc(-c2ncnc(-c3ccc(OCC(CC)CCCC)cc3O)n2)c(O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.40
ALDH1A1 P00352 6/20 0.39
MAPK1 P28482 3/20 0.39
TSHR P16473 2/20 0.39
CYP3A4 P08684 3/20 0.38
NPC1 O15118 2/20 0.38
GAA P10253 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
CA2 P00918 1/20 0.38
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 2/20 0.37
PRSS1 P07477 1/20 0.34
PRSS2 P07478 1/20 0.34
PRSS3 P35030 1/20 0.34
ATM Q13315 2/20 0.33
XBP1 P17861 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29365165 1.00 LMNA (0.40) LMNAALDH1A1MAPK1TSHRCYP3A4
SCHEMBL7217044 0.94 LMNA (0.42) LMNAALDH1A1MAPK1TSHRCYP3A4
SCHEMBL18979221 0.92 LMNA (0.40) LMNAALDH1A1MAPK1TSHRCYP3A4
SCHEMBL473811 0.92 LMNA (0.41) LMNAALDH1A1MAPK1TSHRNPC1
SCHEMBL30111341 0.92 LMNA (0.41) LMNAALDH1A1MAPK1TSHRNPC1
SCHEMBL28003393 0.92 LMNA (0.35) LMNAALDH1A1MAPK1TSHRCYP3A4
SCHEMBL12802481 0.92 LMNA (0.35) LMNAALDH1A1MAPK1TSHRCYP3A4
SCHEMBL28535053 0.91 LMNA (0.40) LMNAALDH1A1MAPK1TSHRCYP3A4
SCHEMBL28344806 0.91 LMNA (0.39) LMNAALDH1A1MAPK1TSHRCYP3A4
SCHEMBL27481297 0.90 LMNA (0.40) LMNAALDH1A1MAPK1TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 519 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007110415-A2 USE OF DIACETYL TRIMERS AND COSMETIC OR THERAPEUTIC FORMULATIONS CONTAINING THESE COMPOUNDS SYMRISE GMBH & CO. KG (DE) 2007-10-04 WO claimed
EP-4103144-B1 COMPOSITIONS COMPRISING UV-FILTERS AND ONE OR MORE (BIO)-ALKANEDIOLS SYMRISE AG (DE) 2026-05-27 EP disclosed
EP-4110277-B1 COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS SYMRISE AG (DE) 2026-04-22 EP disclosed
EP-3045161-B1 Use of active mixtures of 1,2-hexanediol and 1,2-octanediol in cosmetic, pharmaceutical or dermatological emulsions SYMRISE AG (DE) 2026-03-25 EP disclosed
EP-4025675-B1 A PERFUME OIL MIXTURE SYMRISE AG (DE) 2026-03-18 EP disclosed
EP-4706780-A2 COMPOSITIONS COMPRISING UV-FILTERS AND ONE OR MORE (BIO)-ALKANEDIOLS Symrise AG (DE) 2026-03-11 EP disclosed
US-20260034042-A1 Composition with Improved SPF and UVA Photoprotection SYMRISE AG (DE) 2026-02-05 US disclosed
EP-4110276-B1 COMPOSITIONS COMPRISING ALKANEDIOLS SYMRISE AG (DE) 2026-01-28 EP disclosed
US-12421474-B2 Perfume oil mixture SYMRISE AG (DE) 2025-09-23 US disclosed
EP-4616840-A2 COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS WITH ANTIMICROBIALS FOR PRODUCT PROTECTION Symrise AG (DE) 2025-09-17 EP disclosed
WO-2005079743-A1 USE OF (2-HYDROXYPHENYL) ALCOHOLS, AND COSMETIC OR THERAPEUTIC FORMULATIONS CONTAINING SAID COMPOUNDS SYMRISE GMBH & CO. KG (DE) 2005-09-01 WO disclosed
WO-2005004601-A1 SECONDARY ALCOHOLS USED AS ANTIMICROBIAL AGENTS SYMRISE GMBH & CO. KG (DE) 2005-01-20 WO disclosed
EP-1326955-B1 MULTI-PHASE SOAP SYMRISE GMBH & CO KG (DE) 2004-12-22 EP disclosed
EP-1466892-A1 Novel indanylidene compounds Symrise GmbH & Co. KG (DE) 2004-10-13 EP disclosed
EP-1341752-B1 NOVEL INDANYLIDENE COMPOUNDS SYMRISE GMBH & CO KG (DE) 2004-08-04 EP disclosed
US-6673756-B2 MULTILAYER; CUTTING, JOINING UNDER PRESSURE SYMRISE GMBH & CO. KG (DE) 2004-01-06 US disclosed
US-20020173436-A1 Multilayer; cutting, joining under pressure SYMRISE GMBH & CO. KG (DE) 2002-11-21 US disclosed
US-20020143203-A1 Novel indanylidene compounds SYMRISE GMBH & CO. KG (DE) 2002-10-03 US disclosed
EP-1005325-A1 COSMETIC USE OF BIS(RESORCINYL)TRIAZINE DERIVATIVES Ciba SC Holding AG (CH) 2000-06-07 EP disclosed
WO-1999008653-A1 COSMETIC USE OF BIS(RESORCINYL)TRIAZINE DERIVATIVES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1999-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143203-A1 Novel indanylidene compounds CUTA, NISCH, ERCC4 LMNA 518/4885ALDH1A1 373/4885MAPK1 4474/4885
US-20260034042-A1 Composition with Improved SPF and UVA Photoprotection TYR, ERG28, CUTA LMNA 1465/4885ALDH1A1 1926/4885MAPK1 3052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.